International Journal of Immunogenetics

Aims & Scope

The International Journal of Immunogenetics (formerly European Journal of Immunogenetics) publishes original contributions on the genetic control of components of the immune system and their interactions in both humans and experimental animals.

The term 'genetic' is taken in its broadest sense to include studies at the evolutionary, molecular, chromosomal functional and population levels in both health and disease.

Examples are: -studies of blood groups and other surface antigens- cell interactions and immune response- receptors, antibodies, complement components and cytokines- polymorphism- evolution of the organisation, control and function of immune system components- anthropology and disease associations- the genetics of immune-related disease: allergy, autoimmunity, immunodeficiency and other immune pathologies- All papers are seen by at least two independent referees and only papers of the highest quality are accepted.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.1
2024	2.30

Journal Rank

Year	Value
2024	9006

Journal Citation Indicator

Year	Value
2024	230

SJR (SCImago Journal Rank)

Year	Value
2024	0.641

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	51

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Human MHC architecture and evolution: implications for disease association studies

  Citation: 185

  Authors: J. A.

• HLA‐DR, DO AND DP TYPING USING PCR AMPLIFICATION AND IMMOBILIZED PROBES

  Citation: 151

  Authors: H., T., A. B., S., R., R., R., P.S.

• DUAL ROLE OF MANNAN‐BINDING PROTEIN IN INFECTIONS: ANOTHER CASE OF HETEROSIS?

  Citation: 151

  Authors: P., M., T., C., A.

• EXPERIMENTAL AUTOIMMUNE ENCEPHALO‐MYELITIS IN MICE: GENETIC CONTROL OF SUSCEPTIBILITY*

  Citation: 113

  Authors: C. C. A.

• DIALLELIC POLYMORPHISM MAY EXPLAIN VARIATIONS OF THE BLOOD CONCENTRATION OF MANNAN‐BINDING PROTEIN IN ESKIMOS, BUT NOT IN BLACK AFRICANS

  Citation: 110

  Authors: P., H. O., J. A. L., L. U., S., A. S., A.

• Discovery of HLA‐B*480102 in Taiwanese

  Citation: 101

  Authors: M. J., C. C., M. H., P. Y., K. L.

• IMMUNOCHEMICAL ASPECTS OF THE MNSs‐BLOOD GROUP SYSTEM

  Citation: 101

  Authors: W., G., H.

• DISCRIMINATION OF HUMAN HLA‐DRB1 ALLELES BY PCR‐SSCP (SINGLE‐STRAND CONFORMATION POLYMORPHISM) METHOD

  Citation: 99

  Authors: M., K., L., S., T., I., K., T.

• What has<scp>GWAS</scp>done for<scp>HLA</scp>and disease associations?

  Citation: 95

  Authors: A. E., U., M. T.

• The complement‐mediated prozone effect in the Luminex single‐antigen bead assay and its impact on <scp>HLA</scp> antibody determination in patient sera

  Citation: 92

  Authors: C., M.

---